Amantadine use in the French prospective NS-Park cohort

Margherita Fabbri; Vanessa Rousseau; Jean-Christophe Corvol; Agnès Sommet; Florence Tubach; Yann De Rycke; Nathalie Bertille; Yajiththa Selvarasa; Stephanie Carvalho; Véronique Chaigneau; Christine Brefel-Courbon; Fabienne Ory-Magne; Samuel Tessier; Melissa Tir; Matthieu Bereau; Wassilios Meissner; Claire Thiriez; Ana Marques; Philippe Remy; Vincent Schneider; Elena Moro; Luc Defebvre; Jean Luc Houeto; Stephane Prange; Alexandre Eusebio; Christian Geny; Solène Frismand; Philippe Damier; Caroline Giordana Reuther; Giovanni Castelnovo; Isabelle Benatru; Anne Doe de Maindreville; Sophie Drapier; David Maltête; Ouhaid Lagha-Boukbiza; Olivier Rascol; Mickael Aubignat; Eloi Magnin; Pr Pierre Burbaud; Pr Dominique Guehl; Alexandra Foubert-Samier; Brice Laurens; Thomas Boraud; Sylvain Vergnet; David Bendetowicz; Thomas Palpacuer; Bérengère Debilly; Philippe Derost; Charlotte Beal; Hayet Salhi; Alice Dormeuil; Aimée Petit; Alban Gravier; Gwendoline Dupont; Lucie Garnier; Valérie Fraix; Anna Castrioto; Sara Meoni; Nicolas Carriere; Teodor Danaila; Chloé Laurencin; Stéphane Thobois; Jean-Philippe Azulay; Frédérique Fluchere; Mahmoud Charif; Marie-Christine Picot; Lucie Hopes; Anne-Gaelle Corbille; Tiphaine Rouaud; Pascal Derkinderen; Cosmin Alecu; Charlotte Heraud; Marie de Verdal; Bertrand Degos; Graziella Mangone; Sara Sambin; Aymeric Lanore; Thomas Courtin; Louise-Laure Mariani; Fouad Khoury; Poornima Menon; Florence Cormier-Dequaire; Emmanuel Flamand-Roze; David Grabli; Elodie Hainque; Marie Vidhaillet; Aurélie Meneret; Cécile Delorme; Cendrine Foucard; Florian von Raison; Alexis Elbaz; Andreas Hartmann; Vincent Leclercq; Solène Ansquer; Frederique Leh; Marion Leclercq; Guillaume Costentin; Christine Brefel Courbon; Clemence Leung; Hélène Catala; Astrid Causel; Emilie Gaiffe; Sandrine Dupouy; Sandrine Villars; Wei-Ho Lai; Rachida Bari; Damien Chevanne; Elodie Durand; Isabelle Rieu; Stephane Bernard; Corinne Garsault; Noel Boudjema; Pascale Grebent; Andrea Kistner; Pierre Pelissier; Valérie Santraine; Thomas Gaudin; Pierre Boutet; Catherine Caire; Manel Nouira; Claudia Verna; Amory Jardel; Salomé Puisieux; Guillemette Clement; Lili Le Monnier; Régis Frenais; Séverine Le Dily; Rachel Chaigneau; Vanessa Ferrier; Elodie David; Leslie Fra; Elsa Foucaran; Carole Dongmo-Kenfack; Florence Beauzor; Mickael Le; Sonia Messar; Sophie Liot; Emilie Rabois; Margaux Bonnaire-Verdier; Françoise Kestens; Rozenn Gourhan; Sandra Lopez-Alfaro; Jean-François Houvenaghel; Mélanie Alexandre; Christine Bourdonnais; Linda Vernon; Ahmed Boumediene; Céline Julie; Aurette Lobstein; Nadine Longato; Marie-Pierre Mitterle; Clélie Philips; Hugo Rummel; Stéphanie Bras; Estelle Harroch; Claudia Gillet

doi:10.1007/s00702-024-02772-4

Back

Amantadine use in the French prospective NS-Park cohort

Journal article

Peer reviewed

Amantadine use in the French prospective NS-Park cohort

Margherita Fabbri, Vanessa Rousseau, Jean-Christophe Corvol, Agnès Sommet, Florence Tubach, Yann De Rycke, Nathalie Bertille, Yajiththa Selvarasa, Stephanie Carvalho, Véronique Chaigneau, …

Journal of Neural Transmission

05/04/2024

DOI: https://doi.org/10.1007/s00702-024-02772-4

Abstract

Parkinson's disease

Amantadine

NS-Park

Motor complications

Objective: To assess amantadine use and associated factors in the patients with Parkinson's disease (PD).Background: Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat "levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres.Methods: Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis).Results: Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12-18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users.Conclusions: About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.

Files and links (1)

url

Find in HALView

Metrics

1 Record Views

See more details

Details

Title: Amantadine use in the French prospective NS-Park cohort
Creators - without role: Margherita Fabbri - Hôpital Purpan
Vanessa Rousseau - Centre d’Investigation Clinique 1436
Jean-Christophe Corvol - French Clinical Research Infrastructure Network
Agnès Sommet - Hôpital Purpan
Florence Tubach - Institut Pierre Louis d‘Épidémiologie et de Santé Publique
Yann De Rycke - Institut Pierre Louis d‘Épidémiologie et de Santé Publique
Nathalie Bertille - Institut Pierre Louis d‘Épidémiologie et de Santé Publique
Yajiththa Selvarasa - Institut du Cerveau
Stephanie Carvalho - French Clinical Research Infrastructure Network
Véronique Chaigneau - French Clinical Research Infrastructure Network
Christine Brefel-Courbon - French Clinical Research Infrastructure Network
Fabienne Ory-Magne - French Clinical Research Infrastructure Network
Samuel Tessier - Centre Régional de PharmacoVigilance [CHU Toulouse]
Melissa Tir - Université de Picardie Jules Verne
Matthieu Bereau - French Clinical Research Infrastructure Network
Wassilios Meissner - University of Otago
Claire Thiriez - French Clinical Research Infrastructure Network
Ana Marques - French Clinical Research Infrastructure Network
Philippe Remy - Institut Mondor de Recherche Biomédicale
Vincent Schneider - Centre Hospitalier Universitaire Dijon Bourgogne
Elena Moro - European Academy of Neurology
Luc Defebvre - Université de Lille
Jean Luc Houeto - Institut d’Epidémiologie Neurologique et de Neurologie Tropicale
Stephane Prange - Université Claude Bernard Lyon 1
Alexandre Eusebio - French Clinical Research Infrastructure Network
Christian Geny - Université de Montpellier
Solène Frismand - Centre Hospitalier Régional et Universitaire de Nancy
Philippe Damier - Centre d'Investigation Clinique de Nantes
Caroline Giordana Reuther - Centre Hospitalier Universitaire de Nice
Giovanni Castelnovo - French Clinical Research Infrastructure Network
Isabelle Benatru - French Clinical Research Infrastructure Network
Anne Doe de Maindreville - French Clinical Research Infrastructure Network
Sophie Drapier - CIC Rennes
David Maltête - French Clinical Research Infrastructure Network
Ouhaid Lagha-Boukbiza - Université de Reims Champagne-Ardenne
Olivier Rascol - Institut des Maladies Neurodégénératives
Mickael Aubignat
Eloi Magnin
Pr Pierre Burbaud
Pr Dominique Guehl
Alexandra Foubert-Samier - Bordeaux Population Health
Brice Laurens
Thomas Boraud
Sylvain Vergnet
David Bendetowicz - Université de Rouen Normandie
Thomas Palpacuer
Bérengère Debilly
Philippe Derost - Centre Hospitalier Universitaire Henri-Mondor
Charlotte Beal
Hayet Salhi
Alice Dormeuil
Aimée Petit
Alban Gravier
Gwendoline Dupont
Lucie Garnier
Valérie Fraix
Anna Castrioto
Sara Meoni
Nicolas Carriere
Teodor Danaila
Chloé Laurencin
Stéphane Thobois - Institut des Sciences Cognitives
Jean-Philippe Azulay
Frédérique Fluchere
Mahmoud Charif
Marie-Christine Picot
Lucie Hopes
Anne-Gaelle Corbille
Tiphaine Rouaud
Pascal Derkinderen
Cosmin Alecu
Charlotte Heraud
Marie de Verdal
Bertrand Degos
Graziella Mangone
Sara Sambin
Aymeric Lanore
Thomas Courtin
Louise-Laure Mariani
David Bendetowicz - Université de Rouen Normandie
Fouad Khoury
Poornima Menon
Florence Cormier-Dequaire - Inserm
Emmanuel Flamand-Roze
David Grabli - Université de Rouen Normandie
Elodie Hainque
Marie Vidhaillet
Aurélie Meneret
Cécile Delorme
Cendrine Foucard
Florian von Raison
Alexis Elbaz
Andreas Hartmann
Vincent Leclercq - Université de Bourgogne
Solène Ansquer
Frederique Leh
Marion Leclercq
Guillaume Costentin
Christine Brefel Courbon
Clemence Leung
Hélène Catala
Astrid Causel
Emilie Gaiffe
Sandrine Dupouy
Sandrine Villars
Wei-Ho Lai
Rachida Bari
Damien Chevanne
Elodie Durand
Isabelle Rieu - Inserm
Stephane Bernard - Institut des Sciences Cognitives
Corinne Garsault
Noel Boudjema
Pascale Grebent
Andrea Kistner
Pierre Pelissier
Valérie Santraine
Thomas Gaudin
Pierre Boutet
Catherine Caire
Manel Nouira
Claudia Verna
Amory Jardel
Salomé Puisieux
Guillemette Clement
Lili Le Monnier
Régis Frenais
Séverine Le Dily
Rachel Chaigneau - French Clinical Research Infrastructure Network
Vanessa Ferrier - Centre Hospitalier Universitaire de Toulouse
Elodie David - Université de Rouen Normandie
Leslie Fra
Elsa Foucaran
Carole Dongmo-Kenfack
Florence Beauzor - Inserm
Mickael Le - Université de Reims Champagne-Ardenne
Sonia Messar
Sophie Liot - Hôpital Pontchaillou
Emilie Rabois
Margaux Bonnaire-Verdier
Françoise Kestens
Rozenn Gourhan
Sandra Lopez-Alfaro
Jean-François Houvenaghel
Mélanie Alexandre - Assistance Publique Hôpitaux de Marseille
Christine Bourdonnais - Inserm
Linda Vernon
Ahmed Boumediene
Céline Julie
Aurette Lobstein
Nadine Longato
Marie-Pierre Mitterle
Clélie Philips
Hugo Rummel
Stéphanie Bras
Estelle Harroch
Claudia Gillet
Publication Details: Journal of Neural Transmission
Identifiers: 9939775509311
Academic Unit: EuroMov Digital Health in Motion - EuroMov DHM
Language: English
Resource Type: Journal article
Local Fields: hal-04575054